Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New combo attack on tough liver cancer

NCT ID NCT04238637

Summary

This study is testing whether adding immunotherapy drugs to a standard targeted radiation treatment helps control advanced bile duct cancer that starts in the liver. It will involve about 50 adults whose cancer cannot be removed by surgery. Patients will receive the radiation treatment, then be assigned to get one or two immunotherapy drugs to see if the combination is safe and more effective.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INTRAHEPATIC CHOLANGIOCARCINOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Clinic Essen Center

    Essen, Germany

  • Hannover Medical School

    Hanover, Germany

  • Munich Clinic Bogenhausen

    Munich, Germany

  • University Hospital Dresden

    Dresden, Germany

  • University Hospital Essen

    Essen, Germany

  • University Hospital Halle

    Halle, Germany

  • University Hospital Jena

    Jena, Germany

  • University Hospital Munich Grosshadern

    Munich, Germany

Conditions

Explore the condition pages connected to this study.